Boehringer In­gel­heim taps a pop­u­lar an­ti­body dis­cov­ery play­er for ac­cess to drug 'li­brary of li­braries'

Over the past two years, Twist Bio­science — one of the most re­lied up­on com­pa­nies in biotech and acad­e­mia for its DNA syn­the­sis ser­vices — has been shift­ing in­to ther­a­peu­tics, strik­ing dozens of deals with phar­ma com­pa­nies for ac­cess to its an­ti­body “li­brary of li­braries.”

But none so far can match the deal they’ve just inked with Boehringer In­gel­heim.

Boehringer will dole out up to $710 mil­lion in mile­stones to use Twist’s li­braries to dis­cov­er an­ti­bod­ies against a broad range of undis­closed tar­gets, the com­pa­nies an­nounced on Thurs­day. The phar­ma gi­ant will al­so pay an undis­closed up­front fee for each pro­gram that takes off.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER